Artificial Intelligence | Machine Learning | Natural Language Processing Engrail Therapeutics | Significantly Reducing Overall Disease Burden


Consumer, Pharmaceuticals, Healthcare, Drug Discovery, Neuroscience, Disease Prevention, Therapeutic San Diego, California, United States

Engrail Therapeutics

Artificial Intelligence | Machine Learning | Natural Language Processing


Engrail Therapeutics | Significantly Reducing Overall Disease Burden

Engrail Therapeutics

Pharmaceuticals, Healthcare, Drug Discovery, Neuroscience, Disease Prevention, Therapeutic


San Diego, California, United States

We are a neuroscience company forging a new direction to reduce the enormous burden of diseases that impact the nervous system. At our core, we unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.

We are forging a new direction to reduce the enormous burden of diseases that impact the nervous system. At our core, we unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization. Our dedicated team is restless about ensuring our therapies ultimately reach patients with life-limiting diseases. 

In spite of the many treatments developed for the neurosciences, there continues to be an immense disease burden on patients and a significant economic impact. Neuroscience has the potential to undergo a transformation. The brain’s complexities and molecular mechanisms — historically challenging to understand — are becoming clearer. Building on this new momentum and scientific understanding, we have a tremendous opportunity to develop and deliver transformative therapies that relieve patients’ overall disease burden.

 
 

   Total Funding: $64M

   Funding Stage: Series A

   Business Stage: Scaling Up

   Market: B2C

   Company Size: 1 to 25

   Founded: 2019

Sep 2021

  • Engrail Therapeutics and The Texas A&M University System Enter Licensing Agreement

Feb 2021

  • Engrail Therapeutics Acquires NeuroCycle Therapeutics

Jul 2020

  • Engrail Therapeutics Strengthens Leadership Team With Key Executive Appointments and Expands Board of Directors
 
 

Date

Round

$ Raised

Investors

08/03/2021

Series A

$32M

Nan Fung Life Sciences

Date : 08/03/2021

Round: Series A

$ Raised: $32M

Investors: Nan Fung Life Sciences

 

For AI/ML Startup Founders

Get introduced to VC/PE/CVC investors

For Investors at VC/PE firms

Get introduced to AI/ML Startup founders or founders at Engrail Therapeutics

 
 
 
 Vikram Sudarsan


Vikram Sudarsan
President and CEO

 Penelope Przekop


Penelope Przekop
Chief Compliance Officer

 Stephen Cunningham


Stephen Cunningham
President and CEO

 Kimberly Vanover


Kimberly Vanover
Chief Scientific Officer

Camilla Wade


Camilla Wade
VP, BD and Commercial Strategy

 
 

Engrail Therapeutics is growing. Want to work at Engrail Therapeutics? Engrail Therapeutics is hiring. Join team at Engrail Therapeutics

 
 
appengine.ai

World's Most Promising AI/ML Startups